Results 211 to 220 of about 1,342,903 (330)
MC-LBTO: secure and resilient state-aware multi-controller framework with adaptive load balancing for SD-IoT performance optimization. [PDF]
Alyanbaawi A +5 more
europepmc +1 more source
Designing programmable logic controller for data acquisition and control
Mehmet Emre Gözütok
openalex +1 more source
Plasma‐based detection of actionable mutations is a promising approach in lung cancer management. Analysis of ctDNA with a multigene NGS panel identified TP53, KRAS, and EGFR as the most frequently altered, with TP53 and KRAS in treatment‐naïve patients and TP53 and EGFR in previously treated patients.
Giovanna Maria Stanfoca Casagrande +11 more
wiley +1 more source
Robust performance optimization of UAV dynamic systems using MPC-PID hybrid control. [PDF]
Zhou W, Zhou L, Yuan T, Chen R, Liu D.
europepmc +1 more source
Aggressive prostate cancer is associated with pericyte dysfunction
Tumor‐produced TGF‐β drives pericyte dysfunction in prostate cancer. This dysfunction is characterized by downregulation of some canonical pericyte markers (i.e., DES, CSPG4, and ACTA2) while maintaining the expression of others (i.e., PDGFRB, NOTCH3, and RGS5).
Anabel Martinez‐Romero +11 more
wiley +1 more source
Nonlinear Adaptive Control of Bipolar Mood Disorder: A New Approach for Quenching the Mood Swing. [PDF]
Hasirci U.
europepmc +1 more source
ERRFI1, a neural crest (NC)‐associated gene, was upregulated in melanoma and negatively correlated with the expression of melanocytic differentiation markers and the susceptibility of melanoma cells toward BRAF inhibitors (BRAFi). Knocking down ERRFI1 significantly increased the sensitivity of melanoma cells to BRAFi.
Nina Wang +8 more
wiley +1 more source
SDN-Oriented 6G Industrial IoT Architecture Design and Application to Optimal RIS Placement and Selection. [PDF]
Chiti F +3 more
europepmc +1 more source
Detection of extrachromosomal circular DNA (eccDNA) in plasma samples from EGFR‐mutated non‐small cell lung cancer patients. Plasma was collected before and during treatment with the EGFR‐tyrosine kinase inhibitor osimertinib. Plasma eccDNA was detected in all cancer samples, and the presence of the EGFR gene on eccDNA serves as a potential biomarker ...
Simone Stensgaard +5 more
wiley +1 more source

